Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 28, 2016; 8(6): 331-339
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331
Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia
Vasily Isakov, Department of Gastroenterology and Hepatology, Institute of Nutrition, Moscow 115446, Russia
Igor Nikitin, Department of Gastroenterology and Hematology, Russian Academy of Sciences, Moscow 117593, Russia
Vladimir Chulanov, Clinical Diagnostics and Research Center, Central Research Institute of Epidemiology, Moscow 111123, Russia
Pavel Ogurtsov, Hospital Medicine, Peoples’ Friendship University of Russia, Moscow 117198, Russia
Ekaterina Lukyanova, Medical Affairs, MSD Pharmaceuticals LLC, Moscow 115093, Russia
Jianmin Long, Janice Wahl, Frans A Helmond, Clinical Research, Merck & Co., Inc., Kenilworth, NJ 07033, United States
Author contributions: Isakov V, Long J, Wahl J and Helmand FA designed the study; Isakov V, Nikitin I, Chulano V and Ogurtsov P enrolled patients; Isakov V, Lukyanova E, Long J and Helmand FA analyzed the data; Isakov V and Helmand FA wrote the first draft; all authors critically reviewed and approved the final draft of the paper.
Supported by Merck & Co., Inc., Kenilworth, NJ, United States.
Institutional review board statement: The protocol P08160 of the study registered at ClinicalTrials.gov with identifier NCT01425203 presented in the manuscript of Isakov V et al “Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia” was reviewed and approved by the Institute of Nutrition (Moscow, Russia) Institutional Review Board.
Clinical trial registration statement: Protocol P08160 (The Effect of Boceprevir in Russian Participants Diagnosed with Chronic Hepatitis C Genotype 1) is registered at ClinicalTrials.gov (Identifier: NCT01425203).
Informed consent statement: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients included in the study.
Conflict-of-interest statement: Isakov V has received research/grant support from MSD, has served as a board member and or consultant for Abbvie, Vertex, Roche, Novartis, Janssen, and Bristol-Myers Squibb; has served on speakers’ bureaus for Bristol-Myers Squibb, Janssen, Roche, and Novartis; and has received travel funding from Bristol-Myers Squibb and MSD Russia. Chulanov V has served on advisory boards for Roche, Bristol-Myers Squibb, Janssen, Novartis, and MSD Russia; has received research grants from Bristol-Myers Squibb; and has served on speakers’ bureaus for Bristol-Myers Squibb, Roche, Janssen, Novartis, Gilead, AbbVie, and MSD. Ogurtsov P has served on advisory boards for Schering-Plough and delivered lectures on behalf of Abbott, Solvay, PRO.MED.CS Praha a.s., and Veropharm. Nikitin I has nothing to disclose. Lukyanova E, Long J, Wahl J and Helmond FA are current employees of Merck & Co., Inc., Kenilworth, NJ, United States.
Data sharing statement: These data were presented in part at the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC, United States.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Vasily Isakov, Professor, Department of Gastroenterology and Hepatology, Institute of Nutrition, Kashirskoe Shosse 21, Moscow 115446, Russia. vasily.isakov@gmail.com
Telephone: +7-499-6130764 Fax: +7-499-6130764
Received: July 3, 2015
Peer-review started: July 3, 2015
First decision: August 26, 2015
Revised: October 7, 2015
Accepted: December 19, 2015
Article in press: December 23, 2015
Published online: February 28, 2016
Peer-review started: July 3, 2015
First decision: August 26, 2015
Revised: October 7, 2015
Accepted: December 19, 2015
Article in press: December 23, 2015
Published online: February 28, 2016
Core Tip
Core tip: Compared to the standard-of care treatment with peginterferon and ribavirin (PR), addition of boceprevir to PR results in a significant increase in rates of sustained virologic response achieved with substantially shorter treatment durations across a broad cross-section of patients with chronic hepatitis C virus infection in Russia.